Literature DB >> 12627859

Pharmacokinetics of a standard dose of cytarabine in a patient with acute promyelocytic leukemia undergoing continuous ambulatory peritoneal dialysis.

Makoto Takeuchi, Takahiro Yamauchi, Isao Yoshida, Ryo Soda, Takanori Ueda, Kiyoshi Takahashi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12627859     DOI： 10.1007/bf02983222

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  9 in total

1.  Drugs in renal failure: dosing guidelines for frequently used drugs in end-stage renal disease and dialysis patients.

Authors:  G Seyffart
Journal:  Blood Purif       Date:  1985       Impact factor: 2.614

2.  High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency.

Authors:  G A Smith; L E Damon; H S Rugo; C A Ries; C A Linker
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

3.  Pharmacologically directed ara-C therapy for refractory leukemia.

Authors:  W Plunkett; S Iacoboni; E Estey; L Danhauser; J O Liliemark; M J Keating
Journal:  Semin Oncol       Date:  1985-06       Impact factor: 4.929

4.  Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia.

Authors:  A L Harris; C Potter; C Bunch; J Boutagy; D J Harvey; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335

5.  Chemotherapy with cytosine arabinoside in a child with Burkitt's lymphoma on maintenance hemodialysis and hemofiltration.

Authors:  J M Pöschl; G Klaus; U Querfeld; R Ludwig; O Mehls
Journal:  Ann Hematol       Date:  1993-07       Impact factor: 3.673

6.  ara-C in plasma and ara-CTP in leukemic cells after subcutaneous injection and continuous intravenous infusion of ara-C in patients with acute nonlymphoblastic leukemia.

Authors:  J O Liliemark; G Gahrton; C Y Paul; C O Peterson
Journal:  Semin Oncol       Date:  1987-06       Impact factor: 4.929

7.  Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine.

Authors:  L E Damon; W Plunkett; C A Linker
Journal:  Cancer Res       Date:  1991-08-15       Impact factor: 12.701

8.  A sensitive and specific radioimmunoassay for 1-beta-D-arabino-furanosylcytosine.

Authors:  N Shimada; T Ueda; T Yokoshima; J Oh-Ishi; T Oh-oka
Journal:  Cancer Lett       Date:  1984-09       Impact factor: 8.679

9.  Sequential methotrexate and 5-fluorouracil in advanced ovarian carcinoma.

Authors:  R C Donehower; N B Rosenshein; J Rotmensch; D S Ettinger
Journal:  Gynecol Oncol       Date:  1987-05       Impact factor: 5.482
  9 in total
  3 in total

1.  Successful treatment of acute promyelocytic leukemia in a patient on hemodialysis.

Authors:  Yoshiki Tsuchiya; Yoshifumi Ubara; Tatsuya Suwabe; Junichi Hoshino; Keiichi Sumida; Rikako Hiramatsu; Eiko Hasegawa; Masayuki Yamanouchi; Noriko Hayami; Yuji Marui; Naoki Sawa; Fumi Takemoto; Kenmei Takaichi
Journal:  Clin Exp Nephrol       Date:  2011-02-05       Impact factor: 2.801

Review 2.  Antimicrobial dosing in acute renal replacement.

Authors:  William H Fissell
Journal:  Adv Chronic Kidney Dis       Date:  2013-01       Impact factor: 3.620

3.  Acute myeloid leukemia in a 38-year-old hemodialyzed patient with von Hippel-Lindau disease.

Authors:  Katarzyna Labno-Kirszniok; Teresa Nieszporek; Andrzej Wiecek; Grzegorz Helbig; Jan Lubinski
Journal:  Hered Cancer Clin Pract       Date:  2013-08-22       Impact factor: 2.857
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.